Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

Kirsten Y Westerhout1 Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands

Walter Bouwmeester1 Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands

Inge Duchesne2 Janssen EMEA, Turnhoutseweg, Beerse, Belgium

Marta Pisini2 Janssen EMEA, Turnhoutseweg, Beerse, Belgium

Marjanne A Piena1 Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands

Francesco Damele3 Janssen-Cilag SpA, Via Michelangelo Buonarroti, Cologno Monzese, Italy

Beatrice Gueron2 Janssen EMEA, Turnhoutseweg, Beerse, Belgium

Maarten Treur1 Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands

Jonathan Belsey4 JB Medical Ltd, Old Brickworks, Little Cornard, United KingdomCorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.